| Period | Period Low | Period High | Performance | |
|---|---|---|---|---|
| 1-Month | 207.000 +0.43% on 09/18/24 | | 230.000 -9.62% on 09/02/24 | -13.120 (-5.94%) since 08/19/24 |
| 3-Month | 204.000 +1.90% on 08/06/24 | | 233.000 -10.78% on 06/24/24 | -15.120 (-6.78%) since 06/19/24 |
| 52-Week | 132.000 +57.48% on 10/10/23 | | 244.000 -14.80% on 05/13/24 | +50.380 (+31.99%) since 09/19/23 |
The use of hydrogen as a fuel would allow mining companies to further reduce their greenhouse gas emissions...
Sales of Remicade, Stelara, and Tremfya cemented J&J as one of the major companies occupying the PsO market...
Merck & Co. currently holds the position as the market leader based on the success of its agent Keytruda in multiple patient populations and across the...
AstraZeneca expected to further consolidate its position over the forecast period with upcoming therapy launches and label expansions...
Increasing investments by enterprises in cybersecurity owing to employees working remotely during the pandemic sparked an M&A boom in the tech sector...
Venclexta will continue to grow during the forecast period, securing its market-leading position despite heavy competition...
Roche’s anti-angiogenesis drug Avastin (bevacizumab) has held a dominant position in the CRC market for many years...
The US is expected to retain its position as the largest market for glioblastoma multiforme in 2030...
The late-stage pipeline also features several relative newcomers, including Fibrogen, Liminal Biosciences, and PharmAkea...
Johnson & Johnson continues to be the market leader in the ulcerative colitis market...
| 3rd Resistance Point | 212.000 |
| 2nd Resistance Point | 211.000 |
| 1st Resistance Point | 209.000 |
| Last Price | 207.060 |
| 1st Support Level | 206.000 |
| 2nd Support Level | 205.000 |
| 3rd Support Level | 203.000 |
| 52-Week High | 244.000 |
| Last Price | 207.060 |
| Fibonacci 61.8% | 201.216 |
| Fibonacci 50% | 188.000 |
| Fibonacci 38.2% | 174.784 |
| 52-Week Low | 132.000 |